Literature DB >> 30942126

Analysis of pulmonary hypertension patient survival after treatment in referral center (data of first Ukrainian register).

Ganna D Radchenko1,2, Iryna O Zhyvylo1, Yuriy M Sirenko1,3.   

Abstract

The aims of the study were: (1) to evaluate the Ukrainian reality of survival in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH); and (2) to determine predictors of death. A total of 281 patients were enrolled (52 [18.5%] with CTEPH, 229 [81.5%] with PAH). Long-term survival (Kaplan-Meier) and its predictors (Stepwise binary logistic regression and Cox's proportional hazards analyses) were evaluated in adult patients with PH (diagnosed by right heart catheterization [RHC]) within a prospective registry at a single referral center in Kyiv, Ukraine. Follow-up period was up to 51 months. The Kaplan-Meier survival rate for the total cohort was 93.3%, 86.8%, and 81.5% at one, two, and three years, respectively. Survival was better in patients with congenital heart diseases (CHD) in comparison with idiopathic PAH (long rank P = 0.002), connective tissue diseases (CTD; long rank P = 0.001) and CTEPH (long rank P = 0.04). Univariate Cox's predictors of death were: functional class IV (odds ratio [OR] = 4.94; 95% confidence interval [CI] = 2.12-11.48), presence of ascites (OR = 4.52; 95% CI = 2.21-9.24), PAH-CTD (OR = 3.07; 95% CI = 1.07-8.87), PAH-CHD (OR = 0.28; 95% CI = 0.11-0.68), HR on treatment > 105 beats per min (OR = 7.85; 95% CI = 1.83-33.69), office systolic BP < 100 mmHg (OR = 2.78; 95% CI = 1.26-6.1), 6MWT on treatment < 340 m (OR = 3.47; 95% CI = 1.01-12.35), NT-proBNP > 300 pg/mL (OR = 4.98; 95% CI = 1.49-16.6), right atrium square > 22 cm2 (OR = 14.2; 95% CI = 1.92-104.89), right ventricular square in diastole (OR = 1.08; 95% CI = 1.03-1.14), right ventricular square in systole (OR = 1.08; 95% CI = 1.02-1.11), mean pressure in right atrium per each 1-mmHg increase (OR = 1.02; 95% CI = 1.02-1.19). In multivariate Cox regression analyses only presence of ascites, office systolic BP < 100 mmHg, CHD etiology of PH, and NT-proBNP > 300 pg/mL were associated with survival.

Entities:  

Keywords:  one referral center cohort study; predictors; pulmonary hypertension; survival

Year:  2019        PMID: 30942126      PMCID: PMC6487776          DOI: 10.1177/2045894019845604

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  3 in total

1.  The spectrum and prevalence of arrhythmia in different clinical pulmonary hypertension groups in Chinese population.

Authors:  Lin Xue; Yi-Cheng Yang; Qing Zhao; Zhi-Hui Zhao; Qi-Xian Zeng; Tao Yang; Qin Luo; Bing-Yang Liu; Xiu-Ping Ma; Zhi-Hong Liu; Chang-Ming Xiong
Journal:  Clin Cardiol       Date:  2022-03-07       Impact factor: 3.287

2.  Characteristics and outcomes of patients with chronic thromboembolic pulmonary hypertension in the era of modern therapeutic approaches: data from the Polish multicenter registry (BNP-PL).

Authors:  Grzegorz Kopeć; Olga Dzikowska-Diduch; Ewa Mroczek; Tatiana Mularek-Kubzdela; Łukasz Chrzanowski; Ilona Skoczylas; Michał Tomaszewski; Małgorzata Peregud-Pogorzelska; Danuta Karasek; Ewa Lewicka; Wojciech Jacheć; Zbigniew Gąsior; Piotr Błaszczak; Katarzyna Ptaszyńska-Kopczyńska; Katarzyna Mizia-Stec; Andrzej Biederman; Dariusz Zieliński; Roman Przybylski; Piotr Kędzierski; Marcin Waligóra; Marek Roik; Marek Grabka; Joanna Orłowska; Aleksander Araszkiewicz; Marta Banaszkiewicz; Sylwia Sławek-Szmyt; Szymon Darocha; Wojciech Magoń; Alicja Dąbrowska-Kugacka; Jakub Stępniewski; Kamil Jonas; Karol Kamiński; Jarosław D Kasprzak; Piotr Podolec; Piotr Pruszczyk; Adam Torbicki; Marcin Kurzyna
Journal:  Ther Adv Chronic Dis       Date:  2021-03-25       Impact factor: 5.091

3.  Short-Term Impact of Iron Deficiency in Different Subsets of Patients with Precapillary Pulmonary Hypertension from an Eastern European Pulmonary Hypertension Referral Center.

Authors:  Ioan Tilea; Dorina Nastasia Petra; Razvan Constantin Serban; Manuela Rozalia Gabor; Mariana Cornelia Tilinca; Leonard Azamfirei; Andreea Varga
Journal:  Int J Gen Med       Date:  2021-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.